Stopping a GLP-1: weight-regain trials make continuing care part of the decision

The first treatment period is not the whole plan

Weight-loss medication is often sold through an opening price and an early progress target. Withdrawal research asks a different question: what happens when an effective treatment is removed? Across studies of semaglutide and tirzepatide, substantial regain followed withdrawal on average, while continued treatment supported maintenance or further loss. ^{[1] [2] [3]}

For someone comparing care, this makes continuity a practical issue before the first order. It does not mean every person must continue the same product indefinitely, or that an individual who stops has failed. The useful decision includes clinical suitability, tolerability, affordability and a plan for changing circumstances. A welcome offer cannot answer all of those questions, even when the initial prescription is appropriate.

STEP 1 followed a subset after both treatment and support ended

The exploratory STEP 1 extension followed 327 participants after the main 68-week period of once-weekly subcutaneous semaglutide targeting 2.4 mg or placebo. Semaglutide recipients in that subset had lost an average 17.3% of starting weight; over the next year they regained 11.6 percentage points, leaving a net loss of 5.6% from baseline. Structured lifestyle intervention ended alongside trial treatment. ^[1]

That last detail matters. This was not a randomized test isolating medication withdrawal while holding every other support constant during the extension. The results describe an important observed trajectory, but they cannot tell us exactly how much regain was due to each changed component. They also concern a followed subset rather than every person originally randomized in the main trial. Both features belong beside the memorable fraction of prior loss regained.

STEP 4 randomized continuation after an initial run-in

STEP 4 used a different design. After a 20-week run-in reaching subcutaneous semaglutide 2.4 mg once weekly, 803 participants were randomized to continue treatment or switch to placebo, with lifestyle intervention continuing. From week 20 to week 68, average weight changed by minus 7.9% with continued semaglutide and plus 6.9% after the switch. ^[2]

The comparison more directly addresses withdrawal after initial treatment. It also selects people who reached the point of randomization after the run-in. Someone who cannot tolerate the initial phase is not represented in the same way by that later comparison. A strong maintenance result should not be used to erase the practical difficulty of getting to maintenance. During the randomized phase, gastrointestinal events occurred in 41.9% with continued semaglutide and 26.1% with placebo; adverse-event discontinuations were 2.4% and 2.2%, respectively. These are outcomes in the selected run-in population, not estimates for every new starter. ^[2]

SURMOUNT-4 asked the question with tirzepatide

SURMOUNT-4 included a 36-week open-label period of once-weekly subcutaneous tirzepatide at the maximum tolerated 10 mg or 15 mg dose, followed by randomization of 670 participants to continue treatment or switch to placebo for 52 weeks. The randomized participants had lost an average 20.9% during the initial period. From randomization, weight changed by minus 5.5% with continued treatment and plus 14.0% with placebo. ^[3]

These percentages use the weight at randomization as the reference for the later period, not the original starting weight. It would be incorrect simply to subtract the later percentage from the initial one as though the denominators were identical. The study reported net losses from the original baseline separately. Its most common adverse events were mainly mild to moderate gastrointestinal events, reported more often with continued tirzepatide than placebo. ^[3] Keeping those reference points straight is essential when comparing a graph, a marketing claim and an individual's actual progress record.

The studies do not establish a tapering schedule

The three reports examine particular continuation or withdrawal designs. They do not provide a tested universal sequence for reducing doses, spacing injections or replacing treatment with a supplement. ^{[1] [2] [3]} A person should not construct that sequence from an average regain figure or an online account from someone whose clinical circumstances may differ.

The missing evidence is specific: an intervention that changes treatment in a proposed way, with an appropriate comparison and follow-up. Without that, a plausible maintenance theory remains a theory. Discuss any change with the prescribing clinician, especially when treatment affects other conditions or medications. The need for individualized care is not answered by insisting that everyone either stops or continues forever. Those absolutes exceed the question the studies actually tested.

Financial continuity is part of clinical practicality

The maintenance evidence gives a buyer a reason to examine the renewal bill, refill process and care-transfer options before choosing a service. This is an inference about practical planning, not an outcome randomized in the trials. A patient may need to change care because of cost, insurance, access or a clinical decision even when the medication has helped.

Keep the exact preparation, prescribed amount and treatment history available so that a new clinician can evaluate the situation. An administrative cancellation should not become the only plan for what happens next. Similarly, a clinical change does not necessarily cancel an account's renewal. Separating those two tasks can prevent an avoidable gap in communication or an unwanted shipment while the medical decision is being reconsidered.

To examine how ongoing support changes an online-care comparison, read the Direct Meds review.

Plan for change without assuming failure

The weight trajectories in withdrawal studies are averages, with individual variation. ^{[1] [2] [3]} They are useful for setting expectations and discussing continued care, but they do not predict one person's exact response. A stable weight after stopping would not invalidate the research, and regain would not establish poor motivation. The relevant question is what care is suitable now, given the person's health and circumstances.

A good long-term arrangement can explain what it intends to monitor, when reassessment is needed and how treatment can change safely. Compare services on that ability as well as their prices. The strongest lesson from withdrawal research is to include the next phase in the original decision, while allowing the clinical plan to evolve. That is a more useful starting point than treating either an early success or a later regain as the whole story.

Follow-up should also put weight alongside the evidence on lean mass and physical function.